|Mr. Andrew David William Newland||Founder, CEO & Exec. Director||446k||N/A||1962|
|Mr. Ian Francis Griffiths||CFO, Fin. Director, Company Sec. & Exec. Director||284k||N/A||1965|
|Mr. Martin Cooke||Director of Operations & Regulatory Affairs||N/A||N/A||1969|
|Mr. Andrew John Holder||Head of Investor Relations||N/A||N/A||1968|
|Mr. Paul Smith||Chief Commercial Officer||N/A||N/A||N/A|
|Dr. Madeline Repollet||Head of Clinical Laboratories||N/A||N/A||N/A|
|Ms. Anne-Sophie Pailhes-Jimenez||Head of R&D - ANGLE Europe Ltd.||N/A||N/A||N/A|
|Mr. Michael O'Brien||Bus. Devel. Director||N/A||N/A||N/A|
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiplex analysis system for routine and focused multiplex analysis of DNA, RNA or protein biomarkers. The company was founded in 1994 and is based in Guildford, the United Kingdom.
ANGLE plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.